Review Article

Selected Aspects in the Pathogenesis of Autoimmune Diseases

**György Nagy,¹ Peter C. Huszthy,² Even Fossum,³ Yrjö Konttinen,⁴
Britt Nakken,² and Peter Szodoray²**

¹Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest 1089, Hungary

²Centre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway

³K.G. Jebsen Center for Influenza Vaccine Research, Institute of Immunology, University of Oslo and Oslo University Hospital, 0372 Oslo, Norway

⁴Department of Medicine, Institute of Clinical Medicine, Helsinki University Central Hospital and ORTON Orthopaedic Hospital of the Invalid Foundation, 0280 Helsinki, Finland

Correspondence should be addressed to Peter Szodoray; szodoray@gmail.com

Received 23 December 2014; Accepted 24 February 2015

Academic Editor: Anshu Agrawal

Copyright © 2015 György Nagy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Autoimmune processes can be found in physiological circumstances. However, they are quenched with properly functioning regulatory mechanisms and do not evolve into full-blown autoimmune diseases. Once developed, autoimmune diseases are characterized by signature clinical features, accompanied by sustained cellular and/or humoral immunological abnormalities. Genetic, environmental, and hormonal defects, as well as a quantitative and qualitative impairment of immunoregulatory functions, have been shown in parallel to the relative dominance of proinflammatory Th17 cells in many of these diseases. In this review we focus on the derailed balance between regulatory and Th17 cells in the pathogenesis of autoimmune diseases. Additionally, we depict a cytokine imbalance, which gives rise to a biased T-cell homeostasis. The assessment of Th17/Treg-cell ratio and the simultaneous quantitation of cytokines, may give a useful diagnostic tool in autoimmune diseases. We also depict the multifaceted role of dendritic cells, serving as antigen presenting cells, contributing to the development of the pathognomonic cytokine signature and promote cellular and humoral autoimmune responses. Finally we describe the function and role of extracellular vesicles in particular autoimmune diseases. Targeting these key players of disease progression in patients with autoimmune diseases by immunomodulating therapy may be beneficial in future therapeutic strategies.

1. Introduction

Autoimmune diseases are typically multietiological entities, where genetic and environmental abnormalities along with derailed immunoregulatory processes contribute to the development of disease. In the healthy immune system, various tolerance mechanisms, such as activation-induced cell death, anergy, or clonal ignorance, play a protective role to prevent the activation of self-reactive lymphocytes [1]. In autoimmune conditions, self-reactive lymphocytes may not be subjected to the aforementioned tolerance mechanisms raising the possibility of the survival and activation of autoreactive T and B cells upon autoantigen encounter [2–4]. However, there is a fine line between autoimmune

processes, which also appear in healthy individuals and manifested autoimmune diseases. In autoimmune diseases, one or several tolerance mechanisms permanently fail due to the constellation of various environmental factors, specific HLA- and non-HLA genes and/or derailed immunoregulatory processes, leading to the persistence of self-reactive T- and B-cell clones and ultimately organ damage [4, 5]. Immunoregulatory abnormalities and/or the imbalance of immunoregulatory and inflammatory processes could lead to the progression towards autoimmune diseases. Besides faulty tolerance mechanisms, several other factors, such as imbalance of the pro- and anti-inflammatory cytokines, extracellular vesicles, abnormal autoantigen scavenging machinery, and antigen presentation, can contribute to the development

and perpetuation of autoimmune processes and eventually to the progress towards autoimmune diseases. Herein we aim to address some selected pathogenetic points in the development of autoimmune diseases.

2. Animal Models of Autoimmunity

Acquired immunity has evolved with an intricate control system to balance pro- and anti-inflammatory responses. Autoimmunity or immunity toward “self” is a pathological process that involves autoreactive B cells and corresponding autoantigen-specific T cells, imbalances in cytokine levels, and a shifted leukocyte polarization profile. In most of these diseases, a proinflammatory environment dominates, with a Th1 (type 1 insulin-dependent diabetes mellitus, Hashimoto's thyroiditis), Th17 (multiple sclerosis), or combined Th1/Th17 (Sjögren's syndrome) signature. Animal models of autoimmunity have been important research tools for many years now, aiding to pinpoint various components of the pathogenesis of human autoimmune diseases. Today, more than 80 types of autoimmune pathologies are recognized, most with distinct clinical profiles. Animal models have been developed for all the major disease entities, for example, type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome (SS), and systemic lupus erythematosus (SLE). Based on the etiological background and induction of symptoms these animal models can be divided into three broad categories: spontaneous, induced, and genetically engineered. The strengths and weaknesses of each are briefly discussed below.

2.1. Spontaneous Models of Autoimmunity. Susceptible rodent strains spontaneously develop autoimmunity. Well-known examples include the NOD mouse that develops T1D and inbred mice (MRL/lpr, NZB/KN, and Biozzi) that develop arthritis. NOD mice have been extremely useful in delineating the basic principles of T1D [1]. As in humans, so in both NOD mice and susceptible BB rats, T1D is dependent on a collection of genetic traits rather than a single gene [6]. The dependence of T1D on autoreactive T cells and the resolution of disease through T-cell modulation have been important proofs of principles observed in NOD mice. In NOD mice, the sequential development of human T1D is well recapitulated, starting with peri-insulitis (leukocytic infiltration into periductal areas, 3–6 weeks) followed by insulinitis (islets are invaded by inflammatory cells recognizing β -cell autoantigens) and diabetes (T cell-mediated destruction of islets, 10–30 weeks).

A recent spontaneous model for MS is the relapsing-remitting mouse (RR mouse). RR mice harbor increased frequencies of myelin-specific CD4 T cells and are on a SJL/J background [7]. This model is unique, as it resembles human MS in the dependence on autoreactive B cells and the production of autoantibodies and develops without artificial induction [8]. A proof of principle for the contribution of gut microbiota to MS development by T-cell activation has been shown using this model system [9]. Along these lines the contribution of viruses or bacteria as triggers for autoimmune

diseases is an important field of study that would benefit from animal models.

2.2. Induced Models. Systemic autoimmunity may be induced in rodents after injection of the lipid pristane (tetramethylpentadecane; leading to SLE and RA), mercury, or foreign grafts (leading to graft versus host disease, GVHD). Animal models of organ-specific autoimmunity are established by administering a tissue-derived self-antigen (or a peptide thereof) together with a strong adjuvant. Well-known models are collagen induced arthritis (CIA) for RA and experimental allergic encephalomyelitis (EAE) for MS. For CIA, intradermal injection of collagen type II together with adjuvant activates autoreactive B and T cells. In susceptible rat strains, such as DA, Freund's adjuvant alone induces arthritis (AA). CIA successfully recapitulates human RA histopathology, with synovial joint inflammation and bone erosion. Regarding the disease course, pristane-induced arthritis more closely resembles chronic, relapsing-remitting human RA, whereas AA usually shows rapid remission. To induce EAE, CNS antigens in adjuvant are used for immunization or myelin-specific Th1 cells are transferred to susceptible strains, such as Lewis rats. In contrast to human MS, which is relapsing-remitting or develops progressively, EAE induced after T-cell transfer to rats has a monophasic disease course [10]. Although proinflammatory lymphocytic infiltration is achieved, the massive demyelination seen in MS is not consistently recapitulated [11]. A major drawback of inducible models is that they are not suitable to elucidate the etiology of the disease and typically fail to recapitulate the full scale of pathological traits associated with human autoimmunity. The disease course in humans with a given diagnosis is often diversified, whereas that in the mouse is highly predictable. Within inbred rodent strains, genetic homogeneity, a homogenous environmental milieu, and the evolutionary distance from humans certainly contribute to this effect.

2.3. Genetically Engineered Models. Throughout the 1980s, with the aid of more advanced techniques in cell and molecular biology such as gene cloning and mouse embryonic stem cell manipulation technology, more representative rodent models have been generated. These technologies enabled scientists to generate novel mouse strains with defined genetic changes suspected to contribute to autoimmunity (e.g., expression of defined MHC alleles or selected cytokines). Furthermore, these technologies allowed researchers to clone and sequence T-cell lines specific for autoantigens. The T-cell lines were instrumental for transfer experiments and for engineering T-cell receptor knock-in mice [12]. Transgenic mice that express defined human or mouse MHC class II alleles have been successful in recapitulating a whole range of autoimmune pathologies, most notably multiple sclerosis, chronic inflammatory bowel disease, and myasthenia gravis [13]. Mice engineered to express full length human TNF- α spontaneously develop chronic inflammatory polyarthritis [14]. Proof of principle for TNF- α blockade in treating RA has been obtained in this model, an early success story for translational research. Transgenic expression of the human

T-lymphotropic virus-1 genome leads to the development of arthritis in mice and this model suggested the role of this virus in the development of human RA [15, 16]. A major advantage of such genetically engineered models is that the induced changes (genes) can be precisely defined and experimentally controlled through comparisons with the parental background strain. Furthermore, they allow for spatial and temporal control of gene expression, through tissue specific or inducible promoters. In addition, expression of a fluorescent or luminescent reporter facilitates *in vivo* imaging approaches.

2.4. General Considerations. Ideally, an animal model should reflect the whole range of features associated with human pathology, not only isolated traits thereof. If it is a genetically targeted model, it should rely on homologues of genes/pathways known to be responsible for autoimmunity in humans. Finally, it is desirable that the disease develops spontaneously, so that the etiology of the given syndrome may be investigated. Although none of the animal models have all these features, they have, in concert, been invaluable tools that have shed light on basic disease mechanisms. This has been important, since in many human autoimmune diseases, progression is typically correlated only to serum markers with the pathological tissue being inaccessible (such as T1D or MS) or limited (RA or SS). With the application of more refined imaging techniques, such as PET/CT and intravital microscopy, animal models will continue to provide useful mechanistic insights into metabolic parameters, disease course, and pathways of leukocyte migration. We argue that for any given autoimmune disease, scientific evidence collected from several animal models, inducible, genetically modified, and spontaneous, correlated with clinical parameters and characterization of biopsy/autopsy tissue will be needed to extract more biological information with relevance to human pathology.

3. The Role of Regulatory T Cells in Autoimmune Diseases

The fine balance between pro- and anti-inflammatory processes within the immune system is crucial to maintain the antigenic integrity of the individual, while at the same time must effectively eliminate pathogens. A spectrum of characteristic immunocompetent cell populations exists, which have the capability to suppress immune and autoimmune processes. These suppressor activities can be achieved by either cell-cell contact or via anti-inflammatory soluble mediators, for example, anti-inflammatory cytokines. A key member of the family of immunoregulatory cells is denoted as regulatory T cells (Tregs). Tregs derive either from the thymus [$CD4^+CD25^{bright}FoxP3^+$ natural Tregs (nTregs)] or the peripheral blood [IL-10, or TGF- β producing Type-1 regulatory T cells (Tr1)] [17]. Under pathological circumstances, when quantitative and/or qualitative changes in regulatory T cells and proinflammatory immune responses are evoked, on a susceptible genetic background, autoimmune processes can occur, and eventually various autoimmune diseases can develop. In line with this hypothesis, previous studies on

autoimmune disease depicted that the selective decrease in the number of Tregs or, alternatively, a diminished suppressor function of Tregs is characteristic to these diseases (e.g., SLE, Sjögren's syndrome, RA, and MCTD) [18–22]. These data indicate that in patients with established autoimmune diseases a sustained impairment of the regulatory T-cell pool exists.

In order to assess whether regulatory T-cell abnormalities could contribute to the development of autoimmune diseases, it is valuable to assess Tregs in medical conditions, predating the onset of full-blown diseases. In the forerunner medical condition for systemic autoimmune diseases, denoted as undifferentiated connective tissue disease (MCTD), the assessment of Treg cells showed that the percentage and absolute number of natural Tregs ($CD4^+CD25^{bright}FoxP3^+$) were diminished in UCTD patients compared with healthy subjects, while the number of inducible Tregs ($CD4^+IL-10^+$) was increased [23]. This progressive divergent shift in natural and induced Tregs clearly predicted the transition from the UCTD, introductory phase to a well-established systemic autoimmune disease [23]. In active systemic autoimmune diseases, the frequency of natural Tregs was found to be decreased compared to healthy individuals or compared to patients with inactive disease [18, 20, 24]. The other major regulatory T-cell subset denoted as IL-10 producing Type-1 regulatory T cells ($CD4^+IL-10^+$, Tr1) has been investigated and found to have an important role in the development of various autoimmune diseases [25]. IL-10, also known as human cytokine synthesis inhibitory factor (CSIF), is a multifunctional cytokine that can suppress the IFN- γ production of Th1 cells as well as having other important regulatory functions in differentiation of various T-cell subsets, B cells, or NK cells [26, 27]. Previously we have shown a significant increase in the number of IL-10 producing Tr1 cells in UCTD and we found further increase in patients who progressed into definitive systemic autoimmune diseases. We believe that this phenomenon represents a compensatory mechanism in order to downmodulate the effects of the observed IFN- γ overproduction [23].

4. The Role of Th17 Cells and the Th17/Treg Ratio in Autoimmune Diseases

Upon particular, proinflammatory conditions, T cells have the ability to differentiate into IL-17-producing T helper cells, denoted as Th17 cells, and this differentiation is independent of Th1 or Th2 cell development [28, 29]. Th17 polarization in humans requires IL-1 β , IL-6, IL-21, and IL-23, which induce STAT3. While Th17 cells are important in host defense mechanisms against pathogens, the persistent secretion of IL-17 promotes chronic inflammation and is involved in the pathogenesis of inflammatory and autoimmune diseases. Th17 cells recruit neutrophils and macrophages to the site of inflammation; therefore, they are crucial in the initiation of inflammation [29]. As we described, increased levels of Th17 cells and secreted IL-17 have been associated with numerous inflammatory conditions and autoimmune diseases. High levels of IL-17 have been described in the sera, synovial

fluids, and synovial biopsies of most RA patients, while osteoarthritis showed no increased levels of this cytokine [30, 31]. In other systemic autoimmune diseases, IL-17 and Th17 cells may play a role in the pathogenesis, indicated by studies on SLE, or patients with lupus nephritis [32, 33]. In Sjögren's syndrome, an increase in IL-17 has been found in both the serum and the affected salivary glands, indicating that the cytokine may play a part in both development of the glandular and systemic manifestations of the disease [34, 35].

As mentioned earlier, the imbalance of pro- and anti-inflammatory mechanisms, indicated by, for example, Th17 and Treg numbers or function, may initiate and perpetuate autoimmune diseases. Tregs develop in the thymus and participate in the maintenance of peripheral tolerance; however, circulating and local skewed cytokine milieu alters the suppressive function of these cells [36]. Focally, in affected organs of patients with autoimmune diseases increased IL-6 and TGF- β expression has been described, which favors the development of Th17 cells. In addition, increased concentrations of TNF- α , which is pathognomonic to many autoimmune diseases, downmodulate the function of Tregs, further contributing to the disequilibrium between the pro- and anti-inflammatory processes [36].

A clear shift exists in the cytokine homeostasis in a broad spectrum of autoimmune conditions, fueling the predominance of proinflammatory cells versus Tregs [37–46].

5. Cytokine Imbalance, Regulatory/Effector Cells in Various Well-Defined Systemic Autoimmune Diseases

5.1. Sjögren's Syndrome (SS). Sjögren's syndrome (SS) is a chronic, slowly progressive, systemic autoimmune disease that predominantly affects middle-aged women [47]. SS is characterized by mononuclear infiltration and destruction of the exocrine glands, resulting in dry mouth, keratoconjunctivitis sicca, and the presence of other exocrinopathic symptoms [47]. In the pathogenesis, different subsets of T and B lymphocytes and monocytes play a pivotal role. Increased cell activation, disproportional programmed cell death, and faulty autoantigen scavenging are important in the pathogenesis and processes that are partly driven by a skewed cytokine milieu [48, 49]. A group of peripheral cytokines, chemokines, and growth factors have been implicated in the pathogenesis of SS, contributing to the perpetuation of the cellular and humoral autoimmune processes [49–56]. Skewed T-cell subsets and cytokine imbalance seem to play important roles in an orchestrated proinflammatory cascade in SS. Among circulating cytokines, high IFN- γ , along with reduced levels of IL-10, has been described in SS [53]. Moreover, circulating cytokines have the ability to distinguish SS patients with ectopic salivary gland germinal centers, a possible forerunner of lymphoma development in the disease [35, 46, 55]. In patients with SS the following mediators seem to be increased compared to healthy subjects: IL-1 β , IL-2, IL-6, IL-15, IFN- γ , and CCL4 (MIP-1 β) [35]. pSS patients with ectopic germinal center formation were distinguished from

healthy individuals by higher levels of IL-4, IL-10, GM-CSF, IFN- α , CCL3 (MIP-1 α), CCL11 (eotaxin), and B-cell activating factor (BAFF/BLyS), while germinal center positive and negative pSS patients differed in CCL2 (MCP-1) expression. The biomarkers having the strongest discriminatory power amongst SS patients with or without ectopic salivary gland germinal centers were CCL11 (eotaxin) and IFN- γ , as well as BAFF/BLyS [35]. Taken together, these findings suggest that a group of mediators (e.g., cytokines and chemokines) has the ability to steer a proinflammatory milieu in these patients, presumably contributing to a derailed Th17/Treg balance.

5.2. Systemic Sclerosis. Systemic sclerosis (SSc) is a systemic disease of autoimmune pathogenesis, characterized by excessive extracellular matrix deposition and damage of the small blood vessels, leading to inflammatory processes, dominantly in the skin and visceral organs, such as the heart, lungs, or kidneys [57, 58]. Immunoregulatory abnormalities have been depicted in the pathogenesis of SSc [59–62]. Disorders of the immune system lead to chronic inflammatory processes, abnormal T-cell activation, B-cell abnormalities, abundant production of proinflammatory cytokines (e.g., IL-4), and the production of characteristic autoantibodies. Tregs with impaired function have been shown to play a role in the initiation and perpetuation of the disease [61, 62], while increased levels of circulating Th17 cell have been described, along with elevated IL-17 serum concentrations [63, 64]. An altered balance of the Th1 and Th2 cytokines may also be responsible for the development of fibrosis [65]. Patients with SSc had higher percentages of activated T cells, in addition to a population shift between the effector and regulatory T cells. Increased Th17 cell percentages, together with decreased levels of Th1, as well as regulatory T-cell subsets were characteristic of these patients [66]. Interestingly, the functional assessment of Tregs identified that the suppressor activity of Tregs was clearly decreased in SSc, compared to that of healthy individuals. Our data suggest that the increased Th17/Treg ratio and the altered regulatory function of Treg cells play an important role in the development and progression of SSc [40, 66, 67].

5.3. Mixed Connective Tissue Disease. In mixed connective tissue disease (MCTD) the most frequently observed symptoms are arthritis, Raynaud's phenomenon, myositis, esophageal dysmotility, and acrosclerosis along with the presence of autoantibodies reactive with U1 small nuclear RNP (U1RNP) autoantigens [68–76]. Previously we assessed serum cytokines and intracellular cytokine production of CD4⁺ and CD8⁺ T cells in patients with MCTD [76]. Serum concentrations of both type 1 and type 2 cytokines were significantly higher in patients with MCTD than in healthy controls. The percentage of IL-10-producing CD4⁺ and CD8⁺ T cells was higher in patients than in controls. In addition, CD4⁺ and CD8⁺ T cells from patients with active MCTD produced significantly more IL-10 than cells in patients with inactive disease or in healthy individuals [76]. MCTD is characterized by a wide spectrum of T-cell abnormalities, which becomes explicit in the active phase of the disease. Concerning the role of immunoregulatory abnormalities in the pathogenesis,

we assessed Tregs in patients with MCTD. The percentage and the absolute number of natural Treg cells were lower in patients than in healthy controls which further decreased in patients with active disease. Interestingly, we saw an increase in inducible, IL-10 secreting CD4⁺IL-10⁺ Tr1 cells in patients with MCTD. The Tr1 cells ratio further increased in patients with active disease. As we indicated in patients with UCTD, we believe that elevated Tr1 cell percentages could be a compensatory mechanism aiming to restore the balance between type 1 and type 2 cytokines in MCTD [18]. In subsets of MCTD patients, serum levels of IFN- γ and TNF- α were increased along with reduced number of Tregs. The decreased levels of regulatory T cells, along with the increased expression of proinflammatory cytokines, may play a role in the pathogenesis of immune mediated inner ear disorders in MCTD [77].

Serum and intracellular cytokine assessment, reflecting immune-regulatory abnormalities, are valuable biomarkers to assess disease activity in MCTD and are also capable of subcategorizing these patients [78].

5.4. Systemic Lupus Erythematosus (SLE). SLE is a heterogeneous, systemic autoimmune disease with various organ involvements, encompassing mild to moderate forms and also severe, progressive variants [79–81]. A great variety of cytokines have also been implicated in the pathogenesis of SLE, amongst others, BAFF/BLyS, TNF- α , IFN- α , IFN- γ , IL-12, IL-23, IL-18, IL-6, IL-10, and IL-17 [82, 83].

Pinpointing the key role of the interferon signature in SLE, interferon regulatory factor-5 (*IRF5*) has been linked to the increased production of interferon- (IFN-) α , and *STAT4* to the increased sensitivity to IFN- α [84–86]. Patients with disease flare had significant alterations in a wide variety of soluble mediators at baseline with significantly higher levels of proinflammatory mediators, including Th1-, Th2-, and Th17-type cytokines, already several weeks before the appearance of clinical flare compared to clinically stable patients [87]. Regulatory cytokines, including IL-10 and TGF- β , were higher in nonflare SLE patients [87]. Treg-cell number and function have been shown to be impaired in SLE [88–90] along with increases in Th17 cells and serum IL-17 concentrations, in particular in patients with disease flare [91–93]. The Th17 and Treg ratio indicates that SLE is associated with a reduction in the levels and function of immunosuppressive Treg cells together with an increase in the proinflammatory Th17 cells [94].

As we have illustrated, in all these various patient groups with autoimmune conditions, we could identify a circulating cytokine imbalance, a proinflammatory milieu, and the development of Th17 cells along with the reduction in numbers/function of Tregs. The simultaneous, opposing effect of Th17 cells and Tregs has a strong impact on immune homeostasis, deciding and controlling the development of autoimmunity in these patients.

6. Dendritic Cells and Autoimmunity

Dendritic cells (DC) are generally divided into two main classes, the plasmacytoid DCs (pDCs) that react to viral

infections by secreting large amounts of type I interferons and conventional or classical DCs (cDCs) that are important for initiating immune responses through their ability to take up and present antigen to antigen-specific T cells. For efficient priming of T cells and induction of effector cells, the cDCs have to become activated via signals delivered through pathogen recognition receptors such as toll-like receptors (TLRs). Activated cDCs express large amounts of peptide-MHC complexes on their surface and in addition upregulate costimulator molecules such as CD80 and CD86 for efficient priming of antigen specific T cells. Bacterial and viral infections produce a large amount of TLR ligands, such as LPS (TLR2), CpG (TLR9), or dsRNA (TLR3), resulting in activation of cDCs and efficient induction of effector T cells. In the absence of activation, however, it is believed that cDCs instead promote tolerance, through either induction of Treg or T-cell unresponsiveness [95–97]. cDCs therefore play a central role in determining the outcome of the immune response and whether the resulting T-cell responses are immunogenic or tolerogenic.

6.1. Subsets of DCs. Since their initial discovery by Steinman in the early 70s [98], a growing body of information now results in cDCs being divided into subsets based on tissue distribution, surface receptor expression, and functional profiling. In general, cDCs can be divided into lymphoid tissue DC (LT-DCs), in addition to nonlymphoid tissue DC (NLT-DC), or migratory DCs, which source antigen in the periphery and subsequently migrate to draining LN for T-cell priming. LT-DCs were initially divided into subsets based on expression of CD8 α [99] and CD4 [100]. These markers are, however, not optimal when classifying NLT DCs in peripheral organ, with expression of the integrins CD103 and CD11b being more efficient at separating NLT DC populations [101, 102]. While a number of different surface marks have been evaluated, it now seems that the chemokine receptor Xcr1 is one of the more selective markers for identifying LT CD8 α ⁺ DC and the related NLT CD103⁺ DC population [103, 104] and that the integrin Sirpa (CD172a) can be used as a marker for CD4⁺/CD11b⁺ DC [105]. The expression of the markers Xcr1 and Sirpa has the added advantage of being conserved on homologous DC subsets in other species such as man [106, 107], macaques [108], and sheep [109], making for a more unified DC nomenclature across the species.

Both Xcr1⁺ and Sirpa⁺ DCs efficiently present antigens to CD4⁺ T cells [110]. However, functional analysis has indicated that only the Xcr1⁺ DC excel at cross-presenting antigen to CD8⁺ T cell and have subsequently been referred to as cross-presenting DCs [110, 111]. Similar observations have also been made in peripheral tissue with NLT Xcr1⁺ DC (defined as CD103⁺ DC) being better at presenting antigen to CD8⁺ T cells [112]. Whether the same functional difference remains conserved on DC subsets in humans remains a matter of debate, with some studies demonstrating that Xcr1⁺ DC are better at cross-presenting antigens [107], while others have shown similar cross-presentation abilities in Xcr1⁺ and Sirpa⁺ DCs [113].

Dendritic cells have been suggested to be involved in the onset of several different autoimmune diseases [114]. However, the mechanisms by which DC play a role in autoimmunity may vary between diseases. As antigen presenting cells, DC may directly prime autoimmune T cells, but as indicated earlier they may also induce Tregs that inhibit autoimmune disease. In addition, DCs may secrete proinflammatory cytokines upon activation which may be directly involved in disease progression. Here we depict a few examples on the possible involvement of DCs, the progression of type 1 diabetes (T1D), and systemic lupus erythematosus (SLE).

6.2. Type 1 Diabetes (T1D). Type 1 diabetes is thought to be initiated by the presentation of diabetogenic antigens in the draining pancreatic lymph node (pLN), with subsequent induction of autoreactive T cells which destroy the pancreatic β -islet cells leading to loss of insulin production and diabetes. Conditional depletion of DCs has been reported to prevent disease onset in diabetes prone NOD mice, suggesting that DC may be involved in the initial priming of autoreactive T cells [115]. Interestingly, a recent study observed that Batf3 deficient NOD mice did not develop diabetes [116]. Mice deficient in the transcription factor Batf3 lack the Xcr1⁺ LT and NLT DC populations [117], suggesting involvement of this DC subset in the onset of disease. Ferris and colleagues observed that islets of Langerhans contained a minor population of Xcr1⁺ NLT DC, in addition to a major population of macrophages. Deletion of the Xcr1⁺ NLT DC in the NOD.Batf3^{-/-} mice resulted in absence of presentation of MHC-I epitopes in the pLN and no incidence of diabetes. These observations are in accordance with previous studies suggesting that cross priming is required in the pathogenesis of diabetes [118] and the functional specialization of Xcr1⁺ NLT DC in terms of cross presenting antigen to CD8⁺ T cells.

6.3. Systemic Lupus Erythematosus (SLE). While lupus is generally thought to be an autoantibody driven disease, studies have shown that certain MHC haplotypes display a strong association with disease onset suggesting that T cells may also play a role in the pathogenesis [119]. In lupus prone MRL.Fas^{lpr} mice, depletion of DCs resulted in less severe disease development with lower glomerular and interstitial renal disease scores [120]. Interestingly, the authors observed that DC depletion did not significantly influence T-cell activation but that T-cell expansion was severely reduced. Consequently, the immunogenic role of the DCs seems to outweigh the tolerogenic function of DC in this model of autoimmunity. It should be noted that depletion of DCs in this model only ameliorated the disease, suggesting that other cells subsets may be involved in the initiation events. Maybe more surprising was the observation that DC depleted mice displayed reduced numbers of plasmablasts in spleen and inhibited class switching, suggesting that the DCs may be involved in this process. Previous studies have indicated that DC may play a role in plasmablast differentiation in SLE [121], which corresponds well with the observations by Teichmann et al. While DCs in autoimmune disease progression tend to primarily function as antigen presenting cells (APCs) and

activators of T cells, it is clear that their stimulatory effect on B cells may also affect disease progression.

Type I interferons play a major role in disease progression in SLE, and patients with high levels of type I interferon in serum have more severe disease outcome [122]. As highly efficient producers of type I interferons, pDCs have been suggested to be an important source of type I interferon and disease onset in SLE [123]. In human patients, pDCs have been observed to accumulate in the tissue lesions suggesting a possible involvement in lupus [124]. While most observations implicating pDCs in SLE progression have so far been indirect, a recent paper by Sisirak and colleagues showed that impairing pDC function in a murine SLE model nearly abolished disease manifestations such as glomerulonephritis and anti-DNA antibodies [125]. These observations clearly indicate that pDCs are directly involved in SLE pathogenesis and the induction of autoantibodies.

7. Extracellular Vesicles in Autoimmune Diseases

Extracellular vesicles (EVs) are heterogeneous, membrane surrounded structures that can be found in body fluids and play a crucial role in the intracellular communication [126, 127]. Based on their morphological parameters and biogenesis EVs can be categorized as exosomes, microvesicles (MVs), and apoptotic bodies. Exosomes are the smallest EVs; their size range is around 50–100 nm, similar to the size of the viruses. Exosomes are released by exocytosis of multivesicular bodies [128], and they may transfer viruses and microRNA (miRNA). Exosome markers include lysosomal-associated membrane protein 1 (LAMP-1), CD63, and CD81. Among others, several tumor cells and immune cells release exosomes constitutively or upon activation.

The size range of microvesicles (MVs) is between 100 and 1000 nm, similar to the size of bacteria and immune complexes. Detergent treatment (0.05% Triton X-100) completely eliminates the MVs; while it does not significantly influence the immune complexes [129], this method can be used to discriminate MVs and immune complexes. MVs are generated by budding of the plasma membrane. Although platelets, endothelial cells, and red blood cells are the primary sources of MVs, many other cells may release these structures as well. MVs have a central role in the fetomaternal communication and in the pathogenesis of several autoimmune diseases, such as RA and SLE. Phosphatidylserine externalization is a general feature of the MVs. Apoptotic bodies are the largest EVs; their size range is between 1 and 5 μ m (the size range of platelets); they are secreted during apoptosis. Similarly to MVs apoptotic bodies also express phosphatidylserine in the outer part of their membrane and they generally contain DNA. Apoptotic bodies have a central role in the transfer of DNA and oncogenes between various cells. Flow-cytometry, western blotting, ELISA, electron microscopy, and mass spectrometry are the most frequently used methods in the EV research. Despite the widespread research of EVs there are still many technical pitfalls and the researchers have to be especially careful when interpreting their results.

There are increasing data on the potential pathogenetic role of MVs in RA and in SLE. Increased number of platelet derived MVs (PMVs) in the serum and synovial fluid samples of patients with RA were reported [130, 131]. The number of PMVs was increased in the plasma samples of patients with RA compared to the healthy donors, and the number of PMVs correlated with the disease activity [132]. The PMVs have procoagulant activity; therefore PMVs may contribute to the increased cardiovascular risk in RA. It was recently published that C-type lectin-like receptor 2 (CLEC-2) is expressed on the MVs of patients with RA [133], and the authors suggest using this marker to measure PMVs. In general, most studies on MVs in RA investigated morphological features and there are only relatively little data available about their biological effects. Fibroblast-like synoviocytes of patients with RA produced B-cell-activating factor upon MP treatment, suggesting that these structures may contribute to the activation of the adaptive immune response in RA [134].

The number of MPs is increased in SLE and the protein composition of them is different from the healthy donors' [135]. The number of endothelial MVs was measured in a recently published prospective study by flow cytometry [136]. The number of EMPs was higher in the samples of patients with SLE than in the samples of healthy donors. Disease activity decreased during the study and in parallel the number of EMPs decreased. Importantly, the clinical disease activity (BILAG-2004 and SLEDAI-2K scores) did not correlate with the EMP numbers. These data suggest that endothelial dysfunction may improve with the appropriate reduction of the inflammation in SLE. Increased number of MVs were also reported in systemic sclerosis [137] and polymyositis [138] and in Sjögren's syndrome [139].

8. Conclusions

The intricate interplay of various proinflammatory cytokines and chemokines, orchestrated by key regulators of the immune system (e.g., dendritic cell subsets), can lead to the imbalance between regulatory (e.g., Tregs) and proinflammatory cells (e.g., Th17 cells). This vicious circle can further perpetuate autoimmune processes, which, on a susceptible genetic background, can lead to the development of a full-blown autoimmune disease. Other novel mediators, denoted as extracellular vesicles, seem to have a pivotal role in the pathogenesis, as well. The fine mapping of these mediators does not just help us to understand the pathogenesis of these diseases, but we believe that long, empirical therapies can be replaced by optimized combination therapies through personalized proinflammatory cytokine, extracellular vesicle targeting, or dendritic cell manipulation. We believe that this approach will aid in the diagnosis and therapy design in autoimmune diseases and will provide an advanced disease management in the future.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] A. Lleo, P. Invernizzi, B. Gao, M. Podda, and M. E. Gershwin, "Definition of human autoimmunity—autoantibodies versus autoimmune disease," *Autoimmunity Reviews*, vol. 9, no. 5, pp. A259–A266, 2010.
- [2] A. K. Abbas, J. Lohr, B. Knoechel, and V. Nagabhushanam, "T cell tolerance and autoimmunity," *Autoimmunity Reviews*, vol. 3, no. 7-8, pp. 471–475, 2004.
- [3] A. J. S. Davies, "Immunological tolerance and the autoimmune response," *Autoimmunity Reviews*, vol. 7, no. 7, pp. 538–543, 2008.
- [4] J. Ermann and C. G. Fathman, "Autoimmune diseases: genes, bugs and failed regulation," *Nature Immunology*, vol. 2, no. 9, pp. 759–761, 2001.
- [5] G. S. Cooper, F. W. Miller, and J. P. Pandey, "The role of genetic factors in autoimmune disease: implications for environmental research," *Environmental Health Perspectives*, vol. 107, no. 5, pp. 693–700, 1999.
- [6] T. L. Delovitch and B. Singh, "The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD," *Immunity*, vol. 7, pp. 727–738, 1997.
- [7] B. Pöllinger, G. Krishnamoorthy, K. Berer et al., "Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells," *Journal of Experimental Medicine*, vol. 206, no. 6, pp. 1303–1316, 2009.
- [8] K. Berer, H. Wekerle, and G. Krishnamoorthy, "B cells in spontaneous autoimmune diseases of the central nervous system," *Molecular Immunology*, vol. 48, no. 11, pp. 1332–1337, 2011.
- [9] K. Berer, M. Mues, M. Koutrolos et al., "Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination," *Nature*, vol. 479, no. 7374, pp. 538–541, 2011.
- [10] A. Ben-Nun, H. Wekerle, and I. R. Cohen, "The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis," *European Journal of Immunology*, vol. 11, no. 3, pp. 195–199, 1981.
- [11] C. Lington, M. Bradl, H. Lassmann, C. Brunner, and K. Vass, "Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein," *The American Journal of Pathology*, vol. 130, no. 3, pp. 443–454, 1988.
- [12] B. Bogen, L. Gleditsch, S. Weiss, and Z. Dembic, "Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities," *European Journal of Immunology*, vol. 22, no. 3, pp. 703–709, 1992.
- [13] A. K. Mangalam, G. Rajagopalan, V. Taneja, and C. S. David, "HLA class II transgenic mice mimic human inflammatory diseases," *Advances in Immunology*, vol. 97, pp. 65–147, 2008.
- [14] J. Keffer, L. Probert, H. Cazlaris et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," *The EMBO Journal*, vol. 10, no. 13, pp. 4025–4031, 1991.
- [15] Y. Iwakura, M. Tosu, E. Yoshida et al., "Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I," *Science*, vol. 253, no. 5023, pp. 1026–1028, 1991.
- [16] M. Yakova, A. Lézin, F. Dantin et al., "Increased proviral load in HTLV-I-infected patients with rheumatoid arthritis or connective tissue disease," *Retrovirology*, vol. 2, article 4, 2005.

- [17] A. Toda and C. A. Piccirillo, "Development and function of naturally occurring CD4⁺CD25⁺ regulatory T cells," *Journal of Leukocyte Biology*, vol. 80, no. 3, pp. 458–470, 2006.
- [18] S. Baráth, S. Sipka, M. Aleksza et al., "Regulatory T cells in peripheral blood of patients with mixed connective tissue disease," *Scandinavian Journal of Rheumatology*, vol. 35, no. 4, pp. 300–304, 2006.
- [19] C. Dejaco, C. Duftner, B. Grubeck-Loebenstien, and M. Schirmer, "Imbalance of regulatory T cells in human autoimmune diseases," *Immunology*, vol. 117, no. 3, pp. 289–300, 2006.
- [20] M.-F. Liu, C.-R. Wang, L.-L. Fung, and C.-R. Wu, "Decreased CD4⁺CD25⁺ T-cells in peripheral blood of patients with systemic lupus erythematosus," *Scandinavian Journal of Immunology*, vol. 59, no. 2, pp. 198–202, 2004.
- [21] P. Szodoray, G. Papp, I. F. Horvath et al., "Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome," *Clinical and Experimental Immunology*, vol. 157, no. 3, pp. 343–349, 2009.
- [22] X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky, "Deficient CD4⁺CD25^{high} T regulatory cell function in patients with active systemic lupus erythematosus," *The Journal of Immunology*, vol. 178, no. 4, pp. 2579–2588, 2007.
- [23] P. Szodoray, B. Nakken, S. Barath et al., "Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease," *International Immunology*, vol. 20, no. 8, pp. 971–979, 2008.
- [24] J. H. Lee, L. C. Wang, Y. T. Lin, Y. H. Yang, D. T. Lin, and B. L. Chiang, "Inverse correlation between CD4⁺ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus," *Immunology*, vol. 117, no. 2, pp. 280–286, 2006.
- [25] M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, "Interleukin-10-secreting type 1 regulatory T cells in rodents and humans," *Immunological Reviews*, vol. 212, pp. 28–50, 2006.
- [26] S. L. Constant and K. Bottomly, "Induction of Th1 and Th2 CD4⁺ T-cell responses: the alternative approaches," *Annual Review of Immunology*, vol. 15, pp. 297–322, 1997.
- [27] K. W. Moore, R. de Waal Malefyt, R. L. Coffman, and A. O'Garra, "Interleukin-10 and the interleukin-10 receptor," *Annual Review of Immunology*, vol. 19, pp. 683–765, 2001.
- [28] A. O'Garra and N. Arai, "The molecular basis of T helper 1 and T helper 2 cell differentiation," *Trends in Cell Biology*, vol. 10, pp. 542–250, 2000.
- [29] L. Steinman, "A rush to judgment on Th17," *Journal of Experimental Medicine*, vol. 205, no. 7, pp. 1517–1522, 2008.
- [30] S. Kotake, N. Udagawa, N. Takahashi et al., "IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis," *Journal of Clinical Investigation*, vol. 103, no. 9, pp. 1345–1352, 1999.
- [31] S. Y. Hwang and H. Y. Kim, "Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients," *Molecules and Cells*, vol. 19, no. 2, pp. 180–184, 2005.
- [32] M. S. Shin, N. Lee, and I. Kang, "Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells," *Current Opinion in Rheumatology*, vol. 23, no. 5, pp. 444–448, 2011.
- [33] D.-Y. Chen, Y.-M. Chen, M.-C. Wen, T.-Y. Hsieh, W.-T. Hung, and J.-L. Lan, "The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis," *Lupus*, vol. 21, no. 13, pp. 1385–1396, 2012.
- [34] X. Lin, K. Rui, J. Deng et al., "Th17 cells play a critical role in the development of experimental Sjögren's syndrome," *Annals of the Rheumatic Diseases*, 2014.
- [35] P. Szodoray, P. Alex, M. V. Jonsson et al., "Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF," *Clinical Immunology*, vol. 117, no. 2, pp. 168–176, 2005.
- [36] X. Valencia and P. E. Lipsky, "CD4⁺CD25⁺FoxP3⁺ regulatory T cells in autoimmune diseases," *Nature Clinical Practice Rheumatology*, vol. 3, no. 11, pp. 619–626, 2007.
- [37] J. Yang, Y. Chu, X. Yang et al., "Th17 and natural treg cell population dynamics in systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 60, no. 5, pp. 1472–1483, 2009.
- [38] T. Kawanami, T. Sawaki, T. Sakai et al., "Skewed production of IL-6 and TGFβ by cultured salivary gland epithelial cells from patients with Sjögren's syndrome," *PLoS ONE*, vol. 7, no. 10, Article ID e45689, 2012.
- [39] A. Tournadre and P. Miossec, "Interleukin-17 in inflammatory myopathies," *Current Rheumatology Reports*, vol. 14, no. 3, pp. 252–256, 2012.
- [40] G. Papp, I. F. Horvath, S. Barath et al., "Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis," *Clinical Immunology*, vol. 142, no. 2, pp. 150–159, 2012.
- [41] P. Szodoray, P. Alex, N. Knowlton et al., "Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand," *Rheumatology*, vol. 49, no. 10, Article ID keq151, pp. 1867–1877, 2010.
- [42] P. Alex, P. Szodoray, N. Knowlton et al., "Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis," *Clinical and Experimental Rheumatology*, vol. 25, no. 4, pp. 584–592, 2007.
- [43] P. Alex, P. Szodoray, E. Arthur et al., "Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis," *Clinical Rheumatology*, vol. 26, no. 5, pp. 845–848, 2007.
- [44] P. Szodoray, P. Alex, C. M. Chappell-Woodward et al., "Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system," *Rheumatology*, vol. 46, no. 3, pp. 417–425, 2007.
- [45] L. T. Osnes, B. Nakken, E. Bodolay, and P. Szodoray, "Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies—Novel tool for diagnostics and patient follow-up," *Autoimmunity Reviews*, vol. 12, no. 10, pp. 967–971, 2013.
- [46] P. Szodoray, P. Alex, J. G. Brun, M. Centola, and R. Jonsson, "Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system," *Scandinavian Journal of Immunology*, vol. 59, no. 6, pp. 592–599, 2004.
- [47] M. Zeher, "Sjögren's syndrome," in *Research Signpost*, M. Zeher and P. Szodoray, Eds., pp. 1–7, Transworld Research Network, Kerala, India, 2006.
- [48] P. Szodoray and B. Nakken, "Selected molecular aspects behind the clinical picture of Sjögren's syndrome," in *Sjögren's Syndrome and Associated Disorders*, M. Zeher and P. Szodoray, Eds., pp. 27–49, Research Signpost, Transworld Research Network, Kerala, India, 2006.
- [49] F. Ciccia, G. Guggino, A. Giardina et al., "The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome," *Expert Review of Clinical Immunology*, vol. 10, no. 4, pp. 533–541, 2014.

- [50] M. García-Carrasco, J. Font, X. Filella et al., "Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features," *Clinical and Experimental Rheumatology*, vol. 19, no. 4, pp. 411–415, 2001.
- [51] Y. Yao, Z. Liu, B. Jallal, N. Shen, and L. Rönnblom, "Type I interferons in Sjögren's syndrome," *Autoimmunity Reviews*, vol. 12, no. 5, pp. 558–566, 2013.
- [52] R. Jonsson, K. Moen, D. Vestreim, and P. Szodoray, "Current issues in Sjögren's syndrome," *Oral Diseases*, vol. 8, no. 3, pp. 130–140, 2002.
- [53] P. Szodoray, I. Gal, S. Barath et al., "Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines," *Scandinavian Journal of Rheumatology*, vol. 37, no. 3, pp. 205–212, 2008.
- [54] N. C. Kyriakidis, E. K. Kapsogeorgou, and A. G. Tzioufas, "A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms," *Journal of Autoimmunity*, vol. 51, pp. 67–74, 2014.
- [55] A. Awada, C. Nicaise, S. Ena et al., "Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjögren's syndrome," *Annals of the Rheumatic Diseases*, vol. 73, no. 6, pp. 1259–1263, 2014.
- [56] P. Szodoray, I. F. Horvath, G. Papp et al., "The immunoregulatory role of vitamins A, D and E in patients with primary Sjögren's syndrome," *Rheumatology*, vol. 49, no. 2, pp. 211–217, 2010.
- [57] E. C. LeRoy and T. A. Medsger Jr., "Criteria for the classification of early systemic sclerosis," *The Journal of Rheumatology*, vol. 28, no. 7, pp. 1573–1576, 2001.
- [58] W. Lei, Y. Luo, K. Yan et al., "Abnormal DNA methylation in CD4⁺ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis," *Scandinavian Journal of Rheumatology*, vol. 38, no. 5, pp. 369–374, 2009.
- [59] M. Horikawa, M. Hasegawa, K. Komura et al., "Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity," *Journal of Investigative Dermatology*, vol. 125, no. 4, pp. 731–737, 2005.
- [60] V. Ricciari, G. Parisi, A. Spadaro et al., "Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis," *Journal of Rheumatology*, vol. 32, no. 2, pp. 283–286, 2005.
- [61] G. Slobodin, M. S. Ahmad, I. Rosner et al., "Regulatory T cells (CD4⁺CD25^{bright}FoxP3⁺) expansion in systemic sclerosis correlates with disease activity and severity," *Cellular Immunology*, vol. 261, no. 2, pp. 77–80, 2010.
- [62] L. Banica, A. Besliu, G. Pistol et al., "Quantification and molecular characterization of regulatory T cells in connective tissue diseases," *Autoimmunity*, vol. 42, no. 1, pp. 41–49, 2009.
- [63] M. Murata, M. Fujimoto, T. Matsushita et al., "Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?" *Journal of Dermatological Science*, vol. 50, no. 3, pp. 240–242, 2008.
- [64] B. Deleuran and D. J. Abraham, "Possible implication of the effector CD4⁺ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma," *Nature Clinical Practice Rheumatology*, vol. 3, no. 12, pp. 682–683, 2007.
- [65] L. I. Sakkas and C. D. Platsoucas, "Is systemic sclerosis an antigen-driven T cell disease?" *Arthritis & Rheumatism*, vol. 50, no. 6, pp. 1721–1733, 2004.
- [66] G. Papp, I. F. Horvath, S. Barath et al., "Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis," *Scandinavian Journal of Rheumatology*, vol. 40, no. 3, pp. 205–210, 2011.
- [67] G. Papp, S. Barath, A. Szegedi, P. Szodoray, and M. Zeher, "The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis," *Clinical Rheumatology*, vol. 31, no. 9, pp. 1293–1299, 2012.
- [68] G. C. Sharp, W. S. Irvin, E. M. Tan, R. G. Gould, and H. R. Holman, "Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)," *The American Journal of Medicine*, vol. 52, no. 2, pp. 148–159, 1972.
- [69] G. C. Sharp, "Diagnostic criteria for classification of MCTD," in *Mixed Connective Tissue Disease and Antinuclear Antibodies*, R. Kasukawa and G. C. Sharp, Eds., pp. 23–33, Elsevier Science B.V., Amsterdam, The Netherlands, 1987.
- [70] R. Kasukawa, T. Tojo, and S. Miyawaki, "Preliminary diagnostic criteria for classification of mixed connective tissue disease," in *Mixed Connective Tissue Disease and Antinuclear Antibodies*, R. Kasukawa and G. C. Sharp, Eds., pp. 41–47, Elsevier Science B.V., Amsterdam, The Netherlands, 1987.
- [71] R. Hameenkorpi, P. Ruuska, S. Forsberg, A. Tiilikainen, R. Makitalo, and M. Hakala, "More evidence of distinctive features of mixed connective tissue disease," *Scandinavian Journal of Rheumatology*, vol. 22, no. 2, pp. 63–68, 1993.
- [72] J. S. Smolen and G. Steiner, "Mixed connective tissue disease: to be or not to be?" *Arthritis & Rheumatology*, vol. 41, pp. 768–777, 1998.
- [73] R. W. Hoffman and E. L. Greidinger, "Mixed connective tissue disease," *Current Opinion in Rheumatology*, vol. 12, no. 5, pp. 386–390, 2000.
- [74] P. J. Maddison, "Mixed connective tissue disease: overlap syndromes," *Baillière's Best Practice and Research in Clinical Rheumatology*, vol. 14, no. 1, pp. 111–124, 2000.
- [75] M. A. Burdt, R. W. Hoffman, S. L. Deutscher, G. S. Wang, J. C. Johnson, and G. C. Sharp, "Long-term outcome in mixed connective tissue disease," *Arthritis and Rheumatism*, vol. 42, no. 5, pp. 899–909, 1999.
- [76] E. Bodolay, M. Aleksza, P. Antal-Szalmás et al., "Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease," *The Journal of Rheumatology*, vol. 29, no. 10, pp. 2136–2142, 2002.
- [77] A. Hajas, P. Szodoray, S. Barath et al., "Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels," *The Journal of Rheumatology*, vol. 36, no. 9, pp. 1930–1936, 2009.
- [78] A. Hajas, J. Sandor, L. Csathy et al., "Vitamin D insufficiency in a large MCTD population," *Autoimmunity Reviews*, vol. 10, no. 6, pp. 317–324, 2011.
- [79] G. C. Tsokos, "Systemic lupus erythematosus," *The New England Journal of Medicine*, vol. 365, no. 22, pp. 2110–2121, 2011.
- [80] J. Merola, B. Bermas, B. Lu et al., "Clinical manifestations and survival among adults with (SLE) according to age at diagnosis," *Lupus*, vol. 23, no. 8, pp. 778–784, 2014.
- [81] L. D. Heinlen, M. T. McClain, J. Merrill et al., "Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms," *Arthritis & Rheumatism*, vol. 56, no. 7, pp. 2344–2351, 2007.

- [82] M. Aringer and J. S. Smolen, "Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention," *Lupus*, vol. 13, no. 5, pp. 344–347, 2004.
- [83] L. Rönnblom and K. B. Elkon, "Cytokines as therapeutic targets in SLE," *Nature Reviews Rheumatology*, vol. 6, no. 6, pp. 339–347, 2010.
- [84] T. B. Niewold, J. A. Kelly, M. H. Flesch, L. R. Espinoza, J. B. Harley, and M. K. Crow, "Association of the IRF5 risk haplotype with high serum interferon- α activity in systemic lupus erythematosus patients," *Arthritis & Rheumatism*, vol. 58, no. 8, pp. 2481–2487, 2008.
- [85] S. N. Kariuki, K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold, "Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN- α in lupus patients in vivo," *The Journal of Immunology*, vol. 182, no. 1, pp. 34–38, 2009.
- [86] L. Vereecke, R. Beyaert, and G. van Loo, "The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology," *Trends in Immunology*, vol. 30, no. 8, pp. 383–391, 2009.
- [87] M. E. Munroe, E. S. Vista, J. M. Guthridge, L. F. Thompson, J. T. Merrill, and J. A. James, "Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic Lupus erythematosus disease flare," *Arthritis & Rheumatology*, vol. 66, no. 7, pp. 1888–1899, 2014.
- [88] S. Barath, M. Aleksza, T. Tarr, S. Sipka, G. Szegedi, and E. Kiss, "Measurement of natural (CD4+CD25^{high}) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus," *Lupus*, vol. 16, no. 7, pp. 489–496, 2007.
- [89] S. Baráth, P. Soltész, E. Kiss et al., "The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4⁺CD25^{high}FoxP3⁺ regulatory T cells during repeated plasmapheresis treatments of patients," *Autoimmunity*, vol. 40, no. 7, pp. 521–528, 2007.
- [90] M. Bonelli, A. Savitskaya, K. von Dalwigk et al., "Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)," *International Immunology*, vol. 20, no. 7, pp. 861–868, 2008.
- [91] C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. M. Li, P. T. Y. Wong, and C. W. K. Lam, "Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity," *Clinical Immunology*, vol. 127, no. 3, pp. 385–393, 2008.
- [92] C. K. Wong, C. Y. Ho, E. K. Li, and C. W. K. Lam, "Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus," *Lupus*, vol. 9, no. 8, pp. 589–593, 2000.
- [93] A. Doreau, A. Belot, J. Bastid et al., "Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus," *Nature Immunology*, vol. 10, no. 7, pp. 778–785, 2009.
- [94] A. Alunno, E. Bartoloni, O. Bistoni et al., "Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new," *Clinical and Developmental Immunology*, vol. 2012, Article ID 823085, 5 pages, 2012.
- [95] H. C. Probst, K. McCoy, T. Okazaki, T. Honjo, and M. van den Broek, "Resting dendritic cells induce peripheral CD8⁺ T cell tolerance through PD-1 and CTLA-4," *Nature Immunology*, vol. 6, no. 3, pp. 280–286, 2005.
- [96] S. Yamazaki, T. Iyoda, K. Tarbell et al., "Direct expansion of functional CD25⁺ CD4⁺ regulatory T cells by antigen-processing dendritic cells," *The Journal of Experimental Medicine*, vol. 198, no. 2, pp. 235–247, 2003.
- [97] U. Sela, P. Olds, A. Park, S. J. Schlesinger, and R. M. Steinman, "Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice," *The Journal of Experimental Medicine*, vol. 208, no. 12, pp. 2489–2496, 2011.
- [98] R. M. Steinman and Z. A. Cohn, "Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution," *The Journal of Experimental Medicine*, vol. 137, pp. 1142–1162, 1973.
- [99] D. Vremec, M. Zorbas, R. Scollay et al., "The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells," *The Journal of Experimental Medicine*, vol. 176, no. 1, pp. 47–58, 1992.
- [100] D. Vremec, J. Pooley, H. Hochrein, L. Wu, and K. Shortman, "CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen," *Journal of Immunology*, vol. 164, no. 6, pp. 2978–2986, 2000.
- [101] S. Henri, L. F. Poulin, S. Tamoutounour et al., "CD207⁺ CD103⁺ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells," *The Journal of Experimental Medicine*, vol. 207, no. 1, pp. 189–206, 2009.
- [102] F. Ginhoux, K. Liu, J. Helft et al., "The origin and development of nonlymphoid tissue CD103⁺ DCs," *Journal of Experimental Medicine*, vol. 206, no. 13, pp. 3115–3130, 2009.
- [103] B. G. Dorner, M. B. Dorner, X. Zhou et al., "Selective expression of the chemokine receptor CXCR1 on cross-presenting dendritic cells determines cooperation with CD8⁺ T cells," *Immunity*, vol. 31, no. 5, pp. 823–833, 2009.
- [104] K. Crozat, S. Tamoutounour, T.-P. V. Manh et al., "Cutting edge: expression of CXCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8 α + type," *Journal of Immunology*, vol. 187, no. 9, pp. 4411–4415, 2011.
- [105] M. Becker, S. Guttler, A. Bachem et al., "Ontogenic, phenotypic, and functional characterization of CXCR1(+) dendritic cells leads to a consistent classification of intestinal dendritic cells based on the expression of CXCR1 and SIRP α ," *Frontiers in Immunology*, vol. 5, article 326, 2014.
- [106] K. Crozat, R. Guiton, V. Contreras et al., "The CX chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8 α dendritic cells," *Journal of Experimental Medicine*, vol. 207, no. 6, pp. 1283–1292, 2010.
- [107] A. Bachem, S. Guttler, E. Hartung et al., "Superior antigen cross-presentation and CXCR1 expression define human CD11c⁺CD141⁺ cells as homologues of mouse CD8⁺ dendritic cells," *The Journal of Experimental Medicine*, vol. 207, no. 6, pp. 1273–1281, 2010.
- [108] C.-A. Dutertre, J.-P. Jourdain, M. Rancez et al., "TLR3-responsive, CXCR1⁺, CD141(BDCA-3)⁺/CD8 α ⁺-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques," *The Journal of Immunology*, vol. 192, no. 10, pp. 4697–4708, 2014.
- [109] V. Contreras, C. Urien, R. Guiton et al., "Existence of CD8 α -like dendritic cells with a conserved functional specialization and a common molecular signature in distant mammalian species," *Journal of Immunology*, vol. 185, no. 6, pp. 3313–3325, 2010.
- [110] J. L. Pooley, W. R. Heath, and K. Shortman, "Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8⁺

- dendritic cells, but cross-presented to CD8 T cells by CD8⁺ dendritic cells," *The Journal of Immunology*, vol. 166, no. 9, pp. 5327–5330, 2001.
- [111] J. M. M. den Haan, S. M. Lehar, and M. J. Bevan, "CD8⁺ but not CD8⁻ dendritic cells cross-prime cytotoxic T cells in vivo," *The Journal of Experimental Medicine*, vol. 192, no. 12, pp. 1685–1696, 2000.
- [112] S. Bedoui, P. G. Whitney, J. Waithman et al., "Cross-presentation of viral and self antigens by skin-derived CD103⁺ dendritic cells," *Nature Immunology*, vol. 10, no. 5, pp. 488–495, 2009.
- [113] E. Segura, M. Durand, and S. Amigorena, "Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells," *The Journal of Experimental Medicine*, vol. 210, no. 5, pp. 1035–1047, 2013.
- [114] D. Ganguly, S. Haak, V. Sisirak, and B. Reizis, "The role of dendritic cells in autoimmunity," *Nature Reviews Immunology*, vol. 13, no. 8, pp. 566–577, 2013.
- [115] V. Saxena, J. K. Ondr, A. F. Magnusen, D. H. Munn, and J. D. Katz, "The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse," *Journal of Immunology*, vol. 179, no. 8, pp. 5041–5053, 2007.
- [116] S. T. Ferris, J. A. Carrero, J. F. Mohan, B. Calderon, K. M. Murphy, and E. R. Unanue, "A minor subset of *Batf3*-dependent antigen-presenting cells in islets of langerhans is essential for the development of autoimmune diabetes," *Immunity*, vol. 41, no. 4, pp. 657–669, 2014.
- [117] K. Hildner, B. T. Edelson, W. E. Purtha et al., "*Batf3* deficiency reveals a critical role for CD8 α ⁺ dendritic cells in cytotoxic T cell immunity," *Science*, vol. 322, no. 5904, pp. 1097–1100, 2008.
- [118] J. Yamanouchi, J. Verdager, B. Han, A. Amrani, P. Serra, and P. Santamaria, "Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of beta cell autoantigens," *Journal of Immunology*, vol. 171, no. 12, pp. 6900–6909, 2003.
- [119] E. R. Walsh, P. Pisitkun, E. Voynova et al., "Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 40, pp. 16276–16281, 2012.
- [120] L. L. Teichmann, M. L. Ols, M. Kashgarian, B. Reizis, D. H. Kaplan, and M. J. Shlomchik, "Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage," *Immunity*, vol. 33, no. 6, pp. 967–978, 2010.
- [121] H. Joo, C. Coquery, Y. Xue et al., "Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation," *Journal of Experimental Medicine*, vol. 209, no. 7, pp. 1335–1348, 2012.
- [122] L. Bennett, A. K. Palucka, E. Arce et al., "Interferon and granulopoiesis signatures in systemic lupus erythematosus blood," *The Journal of Experimental Medicine*, vol. 197, no. 6, pp. 711–723, 2003.
- [123] L. Rönnblom and G. V. Alm, "A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus," *Journal of Experimental Medicine*, vol. 194, no. 12, pp. F59–F63, 2001.
- [124] S. Blomberg, M. L. Eloranta, B. Cederblad, K. Nordlind, G. V. Alm, and L. Rönnblom, "Presence of cutaneous interferon- α producing cells in patients with systemic lupus erythematosus," *Lupus*, vol. 10, no. 7, pp. 484–490, 2001.
- [125] V. Sisirak, D. Ganguly, K. L. Lewis et al., "Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus," *The Journal of Experimental Medicine*, vol. 211, no. 10, pp. 1969–1976, 2014.
- [126] B. György, T. G. Szabó, M. Pásztói et al., "Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles," *Cellular and Molecular Life Sciences*, vol. 68, no. 16, pp. 2667–2688, 2011.
- [127] E. I. Buzas, B. György, G. Nagy, A. Falus, and S. Gay, "Emerging role of extracellular vesicles in inflammatory diseases," *Nature Reviews Rheumatology*, vol. 10, no. 6, pp. 356–364, 2014.
- [128] J. H. Hurley, E. Boura, L.-A. Carlson, and B. Rózycki, "Membrane budding," *Cell*, vol. 143, no. 6, pp. 875–887, 2010.
- [129] B. György, K. Módos, É. Pállinger et al., "Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters," *Blood*, vol. 117, no. 4, pp. e39–e48, 2011.
- [130] E. Boilard, P. A. Nigrovic, K. Larabee et al., "Platelets amplify inflammation in arthritis via collagen-dependent microparticle production," *Science*, vol. 327, no. 5965, pp. 580–583, 2010.
- [131] B. György, T. G. Szabó, L. Turiák et al., "Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases," *PLoS ONE*, vol. 7, no. 11, Article ID e49726, 2012.
- [132] E. A. J. Knijff-Dutmer, J. Koerts, R. Nieuwland, E. M. Kalsbeek-Batenburg, and M. A. F. J. van de Laar, "Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 46, no. 6, pp. 1498–1503, 2002.
- [133] E. Gitz, A. Y. Pollitt, J. J. Gitz-Francois et al., "CLEC-2 expression is maintained on activated platelets and on platelet microparticles," *Blood*, vol. 124, no. 14, pp. 2262–2270, 2014.
- [134] L. Messer, G. Alsaleh, J.-M. Freyssinet et al., "Microparticle-induced release of B-lymphocyte regulators by rheumatoid synovial cells," *Arthritis Research & Therapy*, vol. 11, article R40, 2009.
- [135] O. Østergaard, C. T. Nielsen, L. V. Iversen et al., "Unique protein signature of circulating microparticles in systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 65, no. 10, pp. 2680–2690, 2013.
- [136] B. Parker, A. Al-Husain, P. Pemberton et al., "Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus," *Annals of the Rheumatic Diseases*, vol. 73, no. 6, pp. 1144–1150, 2014.
- [137] S. Guiducci, J. H. W. Distler, A. Jüngel et al., "The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis," *Arthritis and Rheumatism*, vol. 58, no. 9, pp. 2845–2853, 2008.
- [138] Z. Baka, L. Senolt, J. Vencovsky et al., "Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis," *Immunology Letters*, vol. 128, no. 2, pp. 124–130, 2010.
- [139] E. Bartoloni, A. Alunno, O. Bistoni et al., "Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren's syndrome: new markers of chronic endothelial damage?" *Rheumatology (Oxford)*, vol. 54, no. 3, pp. 536–544, 2015.